FDA 483 - Zimmer, Inc. - July 22, 2011

An FDA inspection of Zimmer Inc. (Medical Device Establishment) conducted from July 6-22, 2011, identified significant deficiencies in their quality system. The primary concerns revolved around the manufacturing and design control of ZMR Hip System implantable femoral prostheses and Titanium Alloy/Trabecular Metal Hip Cups. The inspection revealed that Zimmer Inc. had not fully implemented its Corrective and Preventive Action (CAPA) procedures, failing to identify all necessary actions to prevent the recurrence of ZMR Hip System femoral prosthesis fractures. Numerous patient complaints reported these fractures requiring revision surgeries, yet a previous CAPA was closed without planned corrective actions. Furthermore, design validation for the ZMR Hip System was inadequate, lacking objective data for all body-stem combinations regarding patient weight, activity levels, and proximal bone support that could lead to fractures. The company also failed to establish clear design input and output specifications, leaving critical variables related to device performance undefined. Issues extended to manufacturing processes, where validation of Titanium Alloy/Trabecular Metal Hip Cup diffusion bonding and mechanical rework procedures was found to be deficient. This included inadequate testing parameters, insufficient sample sizes, unverified software programs, and failure to challenge critical process variables across all manufacturing equipment and product configurations. To address these observations, Zimmer Inc. must take comprehensive actions, including fully implementing its CAPA system, performing thorough and objective design validation for all medical devices, establishing clear and measurable design specifications, and ensuring complete process validation for all manufacturing and rework procedures. Additionally, all inspection and testing equipment must be suitable for its intended purpose to ensure product quality and patient safety.